Profactor Pharma

Low-cost, recombinant factor VIII (FVIII) for the treatment of Haemophilia

placeEdinburgh, Scotland, United Kingdom calendar_todayFounded 2009 groups5 employees language profactorpharma.com

Registered entities

Investor mix

38 investors on record; lead investors include Kelvin Capital.

Investor typeCountShare
Venture capital13%
Private equity25%
Other / undisclosed3592%
Coming soon